Mon Aug 20, 2012 6:21pm EDT
Aug 20 (Reuters) - Medtronic Inc said it received European approval for its Viva/Brava portfolio of devices that is used on heart failure patients.
The world's largest maker of medical devices said the products feature a new algorithm, called AdaptivCRTR, that maintains the patients' normal heart rhythms.
Shares of the Minneapolis-based company closed at $41.45 on New York Stock Exchange on Monday.
0 comments:
Post a Comment